This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Clopidogrel, prasugrel and ticagrelor in adults with acute coronary syndrome: a review of the clinical effectiveness, cost effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012
While combination therapy with clopidogrel and ASA remains the basis of antiplatelet therapy in acute coronary syndrome (ACS) patients, each combined therapy of P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) and ASA can be considered for some groups depending on the clinical presentation and subsequent management for patients with ACS.
Subject indexing assigned by CRD
Acute Coronary Syndromes; Adenosine; Cost-Benefit Analysis; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: email@example.com
Date abstract record published